Avadel Pharmaceuticals plc (AVDL)

Avadel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	221.08	169.12	27.96	-	-	22.33
Revenue Growth (YoY)	132.35%	504.79%	-	-	-	-62.28%
Cost of Revenue	22.91	15.28	0.85	-	-	5.74
Gross Profit	198.17	153.84	27.12	-	-	16.59
Selling, General & Admin	184.72	181.04	151.71	74.52	68.5	32.41
Research & Development	16.69	15.2	13.26	20.7	17.1	20.44
Operating Expenses	201.41	196.24	164.97	95.22	85.6	53.25
Operating Income	-3.24	-42.4	-137.85	-95.22	-85.6	-36.66
Interest Expense	-10.12	-10.83	-9.89	-12.34	-9.94	-12.99
Interest & Investment Income	1.18	2.53	-	-	2.44	0.41
Other Non Operating Income (Expenses)	-	-	1.89	1.22	-	-
EBT Excluding Unusual Items	-12.18	-50.7	-145.85	-106.34	-93.1	-49.25
Merger & Restructuring Charges	-	-	-	-3.35	0.05	0.04
Gain (Loss) on Sale of Investments	0.83	1.63	-1.8	-1.75	-0.1	-0.44
Gain (Loss) on Sale of Assets	-	-	-	-	-	45.76
Legal Settlements	-	-	-	-	-	-0.8
Other Unusual Items	5.5	-	-13.13	-	-	-0.4
Pretax Income	-5.85	-49.08	-160.78	-111.44	-93.15	-5.08
Income Tax Expense	-2.92	-0.25	-0.5	26.03	-15.82	-12.11
Earnings From Continuing Operations	-2.92	-48.83	-160.28	-137.46	-77.33	7.03
Net Income	-2.92	-48.83	-160.28	-137.46	-77.33	7.03
Net Income to Common	-2.92	-48.83	-160.28	-137.46	-77.33	7.03
Shares Outstanding (Basic)	97	95	80	60	59	53
Shares Outstanding (Diluted)	97	95	80	60	59	55
Shares Change (YoY)	5.10%	18.67%	33.41%	2.66%	6.54%	46.89%
EPS (Basic)	-0.03	-0.51	-2.00	-2.29	-1.32	0.13
EPS (Diluted)	-0.03	-0.51	-2.00	-2.29	-1.32	0.13
Free Cash Flow	5.27	-46.91	-128.51	-71.02	-77.34	-48.83
Free Cash Flow Per Share	0.06	-0.49	-1.60	-1.18	-1.32	-0.89
Gross Margin	89.64%	90.97%	96.97%	-	-	74.29%
Operating Margin	-1.47%	-25.07%	-492.97%	-	-	-164.15%
Profit Margin	-1.32%	-28.88%	-573.17%	-	-	31.47%
Free Cash Flow Margin	2.38%	-27.74%	-459.57%	-	-	-218.64%
EBITDA	0.36	-39.72	-136.08	-93.72	-84.78	-34.97
EBITDA Margin	0.16%	-23.48%	-	-	-	-156.58%
D&A For EBITDA	3.6	2.68	1.77	1.49	0.82	1.69
EBIT	-3.24	-42.4	-137.85	-95.22	-85.6	-36.66
EBIT Margin	-1.47%	-25.07%	-	-	-	-164.15%
Advertising Expenses	-	-	-	-	-	0.31

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q